{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T08:02:00Z","timestamp":1648800120046},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,12,1]]},"DOI":"10.1093\/jjco\/hyi199","type":"journal-article","created":{"date-parts":[[2005,12,7]],"date-time":"2005-12-07T02:52:43Z","timestamp":1133923963000},"page":"727-732","source":"Crossref","is-referenced-by-count":10,"title":["A Phase II Study of Docetaxel and Cisplatin in Patients with Gastric Cancer Recurring After or Progressing During 5-FU\/Platinum Treatment"],"prefix":"10.1093","volume":"35","author":[{"given":"Hawk","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Hoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Jo","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do-Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Rae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyu Yeol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Joo","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,12,6]]},"reference":[{"key":"key\n\t\t\t\t20171010184359_B1","doi-asserted-by":"crossref","unstructured":"Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol1997;8:163\u20138.","DOI":"10.1023\/A:1008243606668"},{"key":"key\n\t\t\t\t20171010184359_B2","doi-asserted-by":"crossref","unstructured":"Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer1993;72:37\u201341.","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P"},{"key":"key\n\t\t\t\t20171010184359_B3","doi-asserted-by":"crossref","unstructured":"Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer1995;71:587\u201391.","DOI":"10.1038\/bjc.1995.114"},{"key":"key\n\t\t\t\t20171010184359_B4","doi-asserted-by":"crossref","unstructured":"Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry1993;32:2747\u201355.","DOI":"10.1021\/bi00062a003"},{"key":"key\n\t\t\t\t20171010184359_B5","doi-asserted-by":"crossref","unstructured":"Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol2000;11:1263\u20136.","DOI":"10.1023\/A:1008373814453"},{"key":"key\n\t\t\t\t20171010184359_B6","unstructured":"Giuliani F, Gebbia V, De Vita F, Maiello E, Di Bisceglie M, Catalano G, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res2003;23:4219\u201322."},{"key":"key\n\t\t\t\t20171010184359_B7","doi-asserted-by":"crossref","unstructured":"Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol2002;20:1996\u20132004.","DOI":"10.1200\/JCO.2002.08.105"},{"key":"key\n\t\t\t\t20171010184359_B8","doi-asserted-by":"crossref","unstructured":"Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer1999;80:269\u201372.","DOI":"10.1038\/sj.bjc.6690350"},{"key":"key\n\t\t\t\t20171010184359_B9","doi-asserted-by":"crossref","unstructured":"Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol2001;12:47\u201351.","DOI":"10.1023\/A:1008328501128"},{"key":"key\n\t\t\t\t20171010184359_B10","doi-asserted-by":"crossref","unstructured":"Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, et al. Docetaxel (Taxotere)\u2013cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol2000;11:301\u20136.","DOI":"10.1023\/A:1008342013224"},{"key":"key\n\t\t\t\t20171010184359_B11","doi-asserted-by":"crossref","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000;92:205\u201316.","DOI":"10.1093\/jnci\/92.3.205"},{"key":"key\n\t\t\t\t20171010184359_B12","doi-asserted-by":"crossref","unstructured":"Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol2004;15:759\u201364.","DOI":"10.1093\/annonc\/mdh187"},{"key":"key\n\t\t\t\t20171010184359_B13","unstructured":"Eguchi T, Fujii M, Wakabayashi K, Aisaki K, Tsuneda Y, Kochi M, et al. Docetaxel plus 5-fluorouracil for terminal gastric cancer patients with peritoneal dissemination. Hepatogastroenterology2003;50:1735\u20138."},{"key":"key\n\t\t\t\t20171010184359_B14","doi-asserted-by":"crossref","unstructured":"Yoshioka T, Sakata Y, Terashima M, Sekikawa K, Gamoh M, Mitachi Y, et al. Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer. Gastric Cancer2003;6:153\u20138.","DOI":"10.1007\/s10120-003-0244-5"},{"key":"key\n\t\t\t\t20171010184359_B15","doi-asserted-by":"crossref","unstructured":"Mitachi Y, Sakata Y, Ohtsu A, Hyodo I, Katsu K, Sairenji M, et al. Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I\/II study. Gastric Cancer2002;5:160\u20137.","DOI":"10.1007\/s101200200028"},{"key":"key\n\t\t\t\t20171010184359_B16","doi-asserted-by":"crossref","unstructured":"Chen LT, Liu TW, Wu CW, Chung TR, Shiah HS, Jan CM, et al. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil\/leucovorin and cisplatin in patients with advanced gastric cancer. Oncology2002;63:239\u201347.","DOI":"10.1159\/000065471"},{"key":"key\n\t\t\t\t20171010184359_B17","doi-asserted-by":"crossref","unstructured":"Lee SH, Kang WK, Park J, Kim HY, Kim JH, Lee SI, et al. Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br J Cancer2004;91:18\u201322.","DOI":"10.1038\/sj.bjc.6601891"},{"key":"key\n\t\t\t\t20171010184359_B18","doi-asserted-by":"crossref","unstructured":"Lacave AJ, Wils J, Diaz-Rubio E, Clavel M, Planting A, Bleiberg H, et al. cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer Clin Oncol1985;21:1321\u20134.","DOI":"10.1016\/0277-5379(85)90311-6"},{"key":"key\n\t\t\t\t20171010184359_B19","doi-asserted-by":"crossref","unstructured":"Hartmann JT, Quietzsch D, Daikeler T, Kollmannsberger C, Mayer F, Kanz L, et al. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anticancer Drugs1999;10:729\u201333.","DOI":"10.1097\/00001813-199909000-00006"},{"key":"key\n\t\t\t\t20171010184359_B20","doi-asserted-by":"crossref","unstructured":"Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs1998;9:307\u201310.","DOI":"10.1097\/00001813-199804000-00003"},{"key":"key\n\t\t\t\t20171010184359_B21","doi-asserted-by":"crossref","unstructured":"Stathopoulos GP, Rigatos SK, Fountzilas G, Polyzos A, Stathopoulos JG. Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. Oncol Rep2002;9:89\u201392.","DOI":"10.3892\/or.9.1.89"},{"key":"key\n\t\t\t\t20171010184359_B22","doi-asserted-by":"crossref","unstructured":"Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, et al. Docetaxel 75 mg\/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol2002;32:248\u201354.","DOI":"10.1093\/jjco\/hyf057"},{"key":"key\n\t\t\t\t20171010184359_B23","doi-asserted-by":"crossref","unstructured":"Cascinu S, Graziano F, Barni S, Labianca R, Comella G, Casaretti R, et al. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer2001;84:470\u20134.","DOI":"10.1054\/bjoc.2000.1631"},{"key":"key\n\t\t\t\t20171010184359_B24","doi-asserted-by":"crossref","unstructured":"Min YJ, Bang SJ, Shin JW, Kim do H, Park JH, Kim GY, et al. Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer. J Korean Med Sci2004;19:369\u201373.","DOI":"10.3346\/jkms.2004.19.3.369"},{"key":"key\n\t\t\t\t20171010184359_B25","doi-asserted-by":"crossref","unstructured":"Park SH, Choi EY, Bang SM, Cho EK, Lee JH, Shin DB, et al. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. Anticancer Drugs2005;16:621\u20135.","DOI":"10.1097\/00001813-200507000-00005"},{"key":"key\n\t\t\t\t20171010184359_B26","doi-asserted-by":"crossref","unstructured":"Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, et al. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer2005;92:1850\u20134.","DOI":"10.1038\/sj.bjc.6602575"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/35\/12\/727\/5086735\/hyi199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T14:53:26Z","timestamp":1554821606000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jjco\/article\/35\/12\/727\/813252\/A-Phase-II-Study-of-Docetaxel-and-Cisplatin-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2005,12,6]]},"published-print":{"date-parts":[[2005,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyi199","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,12]]},"published":{"date-parts":[[2005,12,1]]}}}